A Clinical Controlled Study Investigating the Efficacy of Xingshen Jieyu Decoction in Treating Post-Stroke Depression Based on Resting-State Default Mode Network Connectivity

INTERVENTION: Integrated Traditional Chinese and Western Medicine group:Xingshen Jieyu Decoction + Escitalopram Oxalate;Traditional Chinese Medicine treatment group:Xingshen Jieyu Decoction;Western medicine treatment group:Escitalopram Oxalate; CONDITION: Post‐stroke Depression PRIMARY OUTCOME: Hamilton depression scale; SECONDARY OUTCOME: Montgomery‐Asberg Depression Rating Scale;Syndrome score of depression in traditional Chinese medicine;National Institutes of Health Stroke Scale;Barthel inde Xscore;Resting‐state functional magnetic resonance imaging;IL33;CX3CL1; INCLUSION CRITERIA: (1) Meet the diagnostic criteria for moderate post‐stroke depression according to Western medicine and for the liver depression and spleen deficiency syndrome according to Traditional Chinese Medicine (TCM) pattern differentiation. (2) Hamilton Depression Scale (HAMD‐17) score: >17 and <24, indicating a diagnosis of moderate depression. (3) Mini‐Mental State Examination (MMSE) score: >17 for illiterate individuals, >20 for those with primary school education, and >24 for those with junior high school education or above, indicating clear consciousness and ability to cooperate with tests and examinations. (4) Age between 18 and 75 years. (5) No use of other antipsychotic or antidepressant medications within the 2 weeks prior to enrollment. (6) Voluntary participation with signed informed consent provided by the patient.